Company to Exhibit in Booth 917 at Boston Atrial Fibrillation Symposium
ST. LOUIS, Jan. 14 /PRNewswire-FirstCall/ -- At the Boston Atrial
Fibrillation Symposium, Stereotaxis, Inc. (Nasdaq: STXS) will showcase three
advances in remote magnetic ablation that it believes will enhance the
efficiency, performance and versatility of its Niobe(R) Magnetic Navigation
System. In booth #917, Stereotaxis will exhibit its new software platform,
Navigant 3.0, with the QuikCAS(TM) Cardiodrive(R) System for enhanced remote
catheter control and improved EP lab workflow, and its partnered magnetic
irrigated catheter, which is now available in Europe.
"Together these three products represent a significant advancement in
remote cardiovascular procedures," said Michael P. Kaminski, Stereotaxis
President and CEO.
-- The QuikCAS Cardiodrive System remotely advances and retracts the
catheter in the patient's heart while the Niobe magnets precisely steer the
catheter's distal tip. The QuikCAS advancements provide the clinician with
greater responsiveness for enhanced performance, a more ergonomic design and
faster set-up for improved workflow.
-- Stereotaxis' partnered magnetic irrigated catheter, now available in
Europe, is widely recognized as the gold standard for complex ablations such
as ventricular tachycardia and complex left atrial arrhythmias. European
clinicians have treated more than 600 patients with the magnetic irrigated
catheter, with extremely positive results. Stereotaxis has prepared a
monograph of these results and will be highlighting the data at the Symposium.
-- Navigant 3.0 is Stereotaxis' new software platform for its Niobe
Magnetic Navigation System. It provides users with many enhanced features and
new capabilities that simplify and accelerate its use, including automated
registration of the 3D mapping system and calibration of the Cardiodrive
System; faster and more accurate automation with re-targeting to compensate
for patient movement; and broader integration with other EP Lab systems.
Particularly when used in combination with Odyssey(TM), Stereotaxis believes
that Navigant 3.0 will significantly advance EP lab productivity and
procedural workflow efficiency.
In addition, clinicians can test drive the full Odyssey information
management solution including its new Odyssey Workstation 3.0 software and the
Odyssey Cinema(TM) data management system for remote viewing and recording of
live interventional cases. From an Odyssey Workstation in booth 917,
clinicians will be able to control a catheter in a beating heart phantom
located 1,200 miles away in the company's St. Louis headquarters. Alongside
the Odyssey Workstation, clinicians can experience Odyssey Cinema for remote
viewing, recording, playback and annotation of synchronized lab information
showing the full context of the procedure. Odyssey Cinema can then broadcast
their case through an Odyssey Connect network link to another hospital on the
global Odyssey network, or during this conference to a partner's booth across
the exhibit hall, allowing clinicians to experience the clear advantages of
the Odyssey network for clinical collaboration, remote consultation, and
training.
"Some 18,000 procedures performed with the Niobe Magnetic Navigation
System have established its reputation for clinical safety, utility, and
efficacy," said Mr. Kaminski. "We continue to innovate and deliver the most
powerful combination of products available to the electrophysiologist, and are
positioned to revolutionize the interventional lab with automation,
information management, and networking."
About Stereotaxis
Stereotaxis designs, manufactures and markets an advanced cardiology
instrument control system for use in a hospital's interventional surgical
suite to enhance the treatment of coronary artery disease and arrhythmias. The
Stereotaxis System is designed to enable physicians to complete more complex
interventional procedures by providing image guided delivery of catheters and
guidewires through the blood vessels and chambers of the heart to treatment
sites. This is achieved using computer-controlled, externally applied magnetic
fields that govern the motion of the working tip of the catheter or guidewire,
resulting in improved navigation, shorter procedure time and reduced x-ray
exposure. The core components of the Stereotaxis system have received
regulatory clearance in the U.S., Europe and Canada.
This press release includes statements that may constitute "forward-
looking" statements, usually containing the words "believe," "estimate,"
"project," "expect" or similar expressions. Forward-looking statements
inherently involve risks and uncertainties that could cause actual results to
differ materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not limited to,
continued acceptance for the Company's products in the marketplace,
competitive factors, changes in government reimbursement procedures,
dependence upon third-party vendors, and other risks discussed in the
Company's periodic and other filings with the Securities and Exchange
Commission. By making these forward-looking statements, the Company undertakes
no obligation to update these statements for revisions or changes after the
date of this release. There can be no assurance that the Company will
recognize revenue related to its purchase orders and other commitments in any
particular period or at all because some of these purchase orders and other
commitments are subject to contingencies that are outside of the Company's
control. In addition, these orders and commitments may be revised, modified or
canceled, either by their express terms, as a result of negotiations, or by
project changes or delays.
SOURCE Stereotaxis, Inc.
-0- 01/14/2009
/CONTACT: Jim Stolze, Chief Financial Officer of Stereotaxis,
+1-314-678-6105; or Investors, Doug Sherk or Jenifer Kirtland,
+1-415-896-6820, or Media, Steve DiMattia, +1-646-201-5445, all of EVC Group,
Inc./
CO: Stereotaxis, Inc.
ST: Missouri
IN: HEA MTC BIO CPR
SU: TDS
EW-DE
-- AQW025 --
1129 01/14/200906:30 ESThttp://www.prnewswire.com